108 related articles for article (PubMed ID: 8573759)
1. The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM.
Nishimura M; Nozaki O; Nakano H; Tsuchida H; Yamada K
J Diabetes Complications; 1995; 9(4):330-3. PubMed ID: 8573759
[TBL] [Abstract][Full Text] [Related]
2. Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus.
Kato H; Takashima T; Kishikawa H; Emura S; Ohmori K
Int J Clin Pharmacol Res; 1996; 16(4-5):99-102. PubMed ID: 9172007
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension.
Friedman R; Mears JG; Barst RJ
Circulation; 1997 Nov; 96(9):2782-4. PubMed ID: 9386137
[TBL] [Abstract][Full Text] [Related]
4. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
Morishita R; Higaki J; Hayashi SI; Yo Y; Aoki M; Nakamura S; Moriguchi A; Matsushita H; Matsumoto K; Nakamura T; Ogihara T
Diabetologia; 1997 Sep; 40(9):1053-61. PubMed ID: 9300242
[TBL] [Abstract][Full Text] [Related]
5. [Research and development of beraprost sodium, a new stable PGI2 analogue].
Nishio S; Nagase H; Kanou K; Aoki S; Kanbayashi Y
Yakugaku Zasshi; 1997 Aug; 117(8):509-21. PubMed ID: 9306726
[TBL] [Abstract][Full Text] [Related]
6. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus.
Goya K; Otsuki M; Xu X; Kasayama S
Metabolism; 2003 Feb; 52(2):192-8. PubMed ID: 12601631
[TBL] [Abstract][Full Text] [Related]
7. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects.
Nony P; Ffrench P; Girard P; Delair S; Azoulay S; Girre JP; Dechavanne M; Boissel JP
Can J Physiol Pharmacol; 1996 Aug; 74(8):887-93. PubMed ID: 8960377
[TBL] [Abstract][Full Text] [Related]
8. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
[TBL] [Abstract][Full Text] [Related]
9. Human prostacyclin platelet receptors in diabetes mellitus.
Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
[TBL] [Abstract][Full Text] [Related]
10. Cytoprotective action of beraprost sodium against peroxide-induced damage in vascular endothelial cells.
Kainoh M; Nishio S; Nakadate T
Pharmacology; 1992; 45(2):61-70. PubMed ID: 1523215
[TBL] [Abstract][Full Text] [Related]
11. [Plasminogen activator inhibitor (PAI-1) and markers of endothelial dysfunction in patients with diabetes mellitus].
Galajda P; Martinka E; Baláz D; Stasko J; Kerný J; Planková E; Mokán M; Kubisz P
Vnitr Lek; 1997 Nov; 43(11):744-7. PubMed ID: 9650506
[TBL] [Abstract][Full Text] [Related]
12. Effects of astaxanthin on blood coagulation, fibrinolysis and platelet aggregation in hyperlipidemic rats.
Deng ZY; Shan WG; Wang SF; Hu MM; Chen Y
Pharm Biol; 2017 Dec; 55(1):663-672. PubMed ID: 27951728
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by beraprost sodium of thrombin-induced increase in endothelial macromolecular permeability.
Imai-Sasaki R; Kainoh M; Ogawa Y; Ohmori E; Asai Y; Nakadate T
Prostaglandins Leukot Essent Fatty Acids; 1995 Aug; 53(2):103-8. PubMed ID: 7480071
[TBL] [Abstract][Full Text] [Related]
14. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
[TBL] [Abstract][Full Text] [Related]
15. Synergistic disaggregation of platelets by the products of endothelial cells or their analogs.
Suzuki Y; Takami H; Tamai Y; Narita M; Mayama K; Munakata A
Haematologia (Budap); 2000; 30(2):81-90. PubMed ID: 10839560
[TBL] [Abstract][Full Text] [Related]
16. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
[TBL] [Abstract][Full Text] [Related]
17. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
Reele SB; Miller OV; Spillers C; Gorman RR
Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420
[TBL] [Abstract][Full Text] [Related]
18. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
Michel G; Seipp U
Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
[TBL] [Abstract][Full Text] [Related]
19. Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM.
Westerveld HT; de Graaf JC; van Breugel HH; Akkerman JW; Sixma JJ; Erkelens DW; Banga JD
Diabetes Care; 1993 May; 16(5):683-8. PubMed ID: 8495604
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation.
Tsutsui K; Shirasaki F; Takata M; Takehara K
Dermatology; 1996; 192(2):120-4. PubMed ID: 8829492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
